SANOFI-ADR (SNY)

US80105N1054 - ADR

50.25  +0.2 (+0.4%)

Fundamental Rating

6

SNY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on SNY. Finally SNY also has an excellent dividend rating.



8

1. Profitability

1.1 Basic Checks

In the past year SNY was profitable.
SNY had a positive operating cash flow in the past year.
Each year in the past 5 years SNY has been profitable.
In the past 5 years SNY always reported a positive cash flow from operatings.

1.2 Ratios

The Return On Assets of SNY (7.85%) is better than 91.15% of its industry peers.
The Return On Equity of SNY (13.40%) is better than 90.10% of its industry peers.
The Return On Invested Capital of SNY (12.90%) is better than 91.67% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 18.14%.
The 3 year average ROIC (7.48%) for SNY is below the current ROIC(12.90%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.85%
ROE 13.4%
ROIC 12.9%
ROA(3y)5.35%
ROA(5y)5.85%
ROE(3y)9.18%
ROE(5y)10.34%
ROIC(3y)7.48%
ROIC(5y)6.88%

1.3 Margins

With an excellent Profit Margin value of 14.17%, SNY belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
In the last couple of years the Profit Margin of SNY has remained more or less at the same level.
Looking at the Operating Margin, with a value of 23.81%, SNY belongs to the top of the industry, outperforming 92.19% of the companies in the same industry.
In the last couple of years the Operating Margin of SNY has grown nicely.
SNY has a better Gross Margin (69.78%) than 75.00% of its industry peers.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
Industry RankSector Rank
OM 23.81%
PM (TTM) 14.17%
GM 69.78%
OM growth 3Y4.23%
OM growth 5Y5%
PM growth 3Y-29.3%
PM growth 5Y-0.74%
GM growth 3Y0.92%
GM growth 5Y0.41%

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so SNY is creating value.
The number of shares outstanding for SNY remains at a similar level compared to 1 year ago.
The number of shares outstanding for SNY has been increased compared to 5 years ago.
SNY has a better debt/assets ratio than last year.

2.2 Solvency

The Debt to FCF ratio of SNY is 2.55, which is a good value as it means it would take SNY, 2.55 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of SNY (2.55) is better than 92.19% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that SNY is not too dependend on debt financing.
SNY has a Debt to Equity ratio (0.22) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 2.55
Altman-Z N/A
ROIC/WACC1.81
WACC7.12%

2.3 Liquidity

SNY has a Current Ratio of 1.28. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.28, SNY is not doing good in the industry: 79.17% of the companies in the same industry are doing better.
A Quick Ratio of 0.38 indicates that SNY may have some problems paying its short term obligations.
SNY has a worse Quick ratio (0.38) than 95.31% of its industry peers.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 0.38

4

3. Growth

3.1 Past

SNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.74%.
Measured over the past years, SNY shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.19% on average per year.
Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 1.25% in the last year.
SNY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.42% yearly.
EPS 1Y (TTM)-8.74%
EPS 3Y10.81%
EPS 5Y8.19%
EPS Q2Q%-17.59%
Revenue 1Y (TTM)1.25%
Revenue growth 3Y7.52%
Revenue growth 5Y5.42%
Sales Q2Q%2.37%

3.2 Future

Based on estimates for the next years, SNY will show a small growth in Earnings Per Share. The EPS will grow by 6.98% on average per year.
Based on estimates for the next years, SNY will show a small growth in Revenue. The Revenue will grow by 5.58% on average per year.
EPS Next Y-5.41%
EPS Next 2Y4.07%
EPS Next 3Y5.48%
EPS Next 5Y6.98%
Revenue Next Year4.75%
Revenue Next 2Y5.85%
Revenue Next 3Y5.86%
Revenue Next 5Y5.58%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 11.94, which indicates a very decent valuation of SNY.
SNY's Price/Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 89.58% of the companies in the same industry.
SNY is valuated cheaply when we compare the Price/Earnings ratio to 29.53, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 10.51, the valuation of SNY can be described as very reasonable.
89.06% of the companies in the same industry are more expensive than SNY, based on the Price/Forward Earnings ratio.
SNY is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 20.94, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 11.94
Fwd PE 10.51

4.2 Price Multiples

SNY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SNY is cheaper than 94.79% of the companies in the same industry.
SNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SNY is cheaper than 86.98% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.94
EV/EBITDA 5.81

4.3 Compensation for Growth

SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.46
EPS Next 2Y4.07%
EPS Next 3Y5.48%

7

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 4.01%, SNY is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 4.02, SNY pays a better dividend. On top of this SNY pays more dividend than 95.83% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.33, SNY pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.01%

5.2 History

The dividend of SNY has a limited annual growth rate of 3.31%.
SNY has paid a dividend for at least 10 years, which is a reliable track record.
SNY has decreased its dividend recently.
Dividend Growth(5Y)3.31%
Div Incr Years1
Div Non Decr Years1

5.3 Sustainability

SNY pays out 44.90% of its income as dividend. This is a bit on the high side, but may be sustainable.
SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP44.9%
EPS Next 2Y4.07%
EPS Next 3Y5.48%

SANOFI-ADR

NASDAQ:SNY (7/17/2024, 2:29:05 PM)

50.25

+0.2 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap125.73B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 4.01%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 11.94
Fwd PE 10.51
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)1.46
Profitability
Industry RankSector Rank
ROA 7.85%
ROE 13.4%
ROCE
ROIC
ROICexc
ROICexgc
OM 23.81%
PM (TTM) 14.17%
GM 69.78%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.28
Quick Ratio 0.38
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-8.74%
EPS 3Y10.81%
EPS 5Y
EPS Q2Q%
EPS Next Y-5.41%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.25%
Revenue growth 3Y7.52%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y